PROTECTIVE EFFECTS OF METFORMIN IN AN IN VITRO MODEL OF PROTEINURIC KIDNEY DISEASE by Allouch, Soumaya
QATAR UNIVERSITY 
COLLEGE OF PHARMACY 
 
PROTECTIVE EFFECTS OF METFORMIN IN AN IN VITRO MODEL 
OF PROTEINURIC KIDNEY DISEASE 
BY 
 
SOUMAYA N. ALLOUCH 
 
A Thesis Submitted to the Faculty of  
Pharmacy 
in Partial Fulfillment  
of the Requirements 
for the Degree of 
Master of Science in Pharmacy 
January 2017 
© 2017 Soumaya Najib Allouch. All rights reserved. 
 
 
 
 
 
ii			
COMMITTEE PAGE 
	
The members of the Committee approve the thesis of Soumaya Allouch defended on 
11/10/2016. 
 
_______________________________________  
Dr. Shankar Munusamy  
Thesis Supervisor 
 
______________________________________  
Dr. Feras Qasem Alali 
Committee Member 
 
_______________________________________  
Dr. Ayman El-Kadi  
Committee Member 
 
_______________________________________  
Dr. Vidya Mohamed Ali  
Committee Member 
 
_______________________________________  
Dr. Ali Hussein Eid  
Committee Member 
 
 
 
 
 
 
 
Approved: 
 
_______________________________________  
Mohamed Diab, Dean of College of Pharmacy  
iii			
 
ABSTRACT 
 
Allouch,	Soumaya,	Masters:	January:	2017,	Pharmacy:	
Title:	PROTECTIVE	EFFECTS	OF	METFORMIN	IN	AN	IN	VITRO	MODEL	OF	PROTEINURIC	KIDNEY	
DISEASE	
Supervisor	of	Thesis:	Shankar	Munusamy	
Albuminuria, a hallmark of chronic kidney disease (CKD), plays a crucial role in the 
etiology of CKD. High albumin levels are thought to induce endoplasmic reticulum (ER) 
stress and activate the AKT pathway, and lead to inactivation of AMP-activated kinase 
(AMPK), an energy-sensing molecule within cells. This in turn, activates mTOR 
(mammalian target of rapamycin), which inhibits autophagy and induces epithelial-to-
mesenchymal transition (EMT), and ultimately results in accelerated renal cell apoptosis. 
Thus, the objectives of this study are: 1) to investigate the effects of restoration of AMPK 
signaling in renal cells using metformin on ER stress, AKT, EMT, autophagy and 
apoptosis that are thought to mediate renal cell injury during proteinuria, and 2) to dissect 
the AMPK- and non-AMPK mediated effects of metformin using an in vitro model of 
albumin-induced renal cell injury. Normal rat kidney proximal tubular (NRK-52E) cells 
grown to 60% confluency were exposed to 10 and 15 mg/ml of albumin for 72 hours in 
the presence or absence of 1 mM Metformin and/or 0.5 µM compound C, (an AMPK 
inhibitor). Cells were assessed for alterations in AMPK, AKT and mTOR pathways, and 
the markers of ER stress, EMT, autophagy and apoptosis. Metformin treatment 
significantly induced phosphorylation of AMPK, and attenuated the phosphorylation of 
AKT and mTOR markers in NRK-52E cells exposed to albumin. More importantly, 
iv			
metformin treatment prevented albumin-mediated induction of α-SMA (an EMT marker) 
and the expressions of pro-apoptotic ER stress marker CHOP and apoptotic caspases -12 
and -3 but augmented the levels of autophagy markers (P-ULK-1 and LC3-II) in renal 
cells. Blockade of metformin-induced AMPK activation with compound C blunted the 
ER defense response and autophagy but had no effect on the markers of EMT (α-SMA) 
and apoptosis (caspase-12 and BAX) in renal cells exposed to albumin. Our studies 
suggest that metformin protects renal cells against proteinuric cytotoxicity via 
suppression of AKT and mTOR activation, EMT and apoptosis, and augmentation of 
autophagy and ER defense response in renal tubular cells. Studies with Compound C 
reveal that metformin’s effects on autophagy and ER chaperone expression were AMPK-
mediated whereas its effects on EMT and apoptosis were AMPK-independent.  
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Chapter 1: Introduction 	
1.1.  CHRONIC KIDNEY DISEASE: DEFINITION, STAGING, EPIDEMIOLOGY 
AND CURRENT THERAPY 
 Kidneys play a pivotal role in the homeostasis of the human body. Under 
physiological conditions, the renal system, through controlling water, hydrogen ions and 
essential electrolytes such as sodium, potassium, and bicarbonate, maintains the 
intravascular volume, acid-base equilibrium, electrolyte and water balance. Chronic 
kidney disease (CKD) is a broad term that refers to diverse disease conditions affecting 
the structure and function of the renal system. CKD is characterized by either the 
existence of renal impairment or the diminution of renal function (1). Glomerular 
filtration rate (GFR), a cornerstone indicator to estimate renal function, is used to 
determine the prognosis and progression of CKD. Based on the GFR, CKD is classified 
into five stages as shown in Table 1.1 (2). 
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Table 1.1.  
Stages of chronic kidney disease based on the glomerular filtration rate (GFR) 
Stages Description Renal Function (ml/min/1.73 m2) 
1 Kidney damage but normal GFR ≥ 90 
2 Mild decreases in GFR 60 to 89 
3 Moderate decrease in GFR 30 to 59 
4 Severe decrease in GFR 15 to 29 
5 End stage renal disease (ESRD) < 15 
 
 
   
 Various factors such as diabetes, hypertension, obesity, aging, and other cardiovascular 
diseases could lead to CKD (Figure 1.1). Irrespective of its etiology, CKD is associated 
with multiple complications ranging from increased hospitalization to aggravated 
cardiovascular events and mortality (3). Worldwide, a trend of a sharp increase in the 
incidence and prevalence of CKD is noted. In the United States, more than 20 million 
adults are estimated to have CKD in 2015 (4). In Qatar, CKD affects about 13% of the 
population and the prevalence of end stage renal disease (the advanced phase of CKD) 
was found to be 212 per million population (5). The increased risk of complications 
associated with CKD combined with the high prevalence of CKD warrants its prevention 
and management as a high national and international priority.  
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Figure 1.1. The different risk factors responsible for the development of CKD in the 
USA. 
 
 
 
The current management of CKD is mainly aimed at slowing the progression of 
renal impairment and albuminuria through the use of angiotensin-converting-enzyme 
(ACE) inhibitors and angiotensin-receptor blockers (ARBs) (1). Nonetheless, these drugs 
were only shown to be beneficial in patients with macroalbuminuria (i.e., the urinary 
albumin to creatinine ratio between 30 to 300 mg/g) and advanced renal impairment (6). 
Furthermore, the existing therapies neither reverse established kidney damage nor restore 
normal renal function (1, 6). Thus, there is an urgent need for therapeutic agents that can 
prevent and/or treat CKD. 
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 1.2. METFORMIN 
Metformin, a chemically derived compound from biguanides (Figure 1.2), is 
considered a cornerstone in the management of type 2 diabetes (T2DM). Metformin’s 
exact mechanism of action is yet to be fully elucidated. Nonetheless, its ability to 
normalize blood glucose levels without the incidence of hypoglycemia in patients is 
shown to be exerted through an increase in insulin sensitivity in the tissues and a decrease 
in hepatic gluconeogenesis and intestinal absorption of glucose (7). Additionally, several 
reports have documented metformin’s ability to improve lipid profile (8), and promote 
weight loss (9) in patients with T2DM and obesity. Numerous studies also reveal the 
potential therapeutic benefits that metformin confers in the management of CKD (7). 
 
 
 
 
Figure 1.2. Structure of Metformin (3-(diaminomethylidene)-1,1-dimethylguanidine). 
 
 
 The renal elimination of metformin in its unchanged form, in conjunction with 
metformin’s tendency to cause lactic acidosis led to its cautious use in patients with 
CKD.  Despite their initial development in 1950, the cautious use of biguanides 
(phenformin and metformin) started only in mid-1970s when phenformin was implicated 
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in a number of fatal cases of lactic acidosis (10). Phenformin was ultimately withdrawn 
from the market due to its lethal metabolic side effects. In spite of its structural similarity 
with phenformin, the incidence of lactic acidosis was 10 to 20 times less frequent with 
metformin (11). Pharmacovigilance reports from France, United Kingdom and Sweden 
showed that the risk for lactic acidosis with metformin is as low as was 2.4 cases per 
100,000 patient-years (12). This is further supported by the very few cases of lactic 
acidosis reported with metformin despite the exponential increase in its use worldwide. 
Eventually in 1995, the U.S. Food and Drug Administration (FDA) approved the use of 
metformin to treat type II diabetes and the risk of lactic acidosis was deemed minimal. 
Nonetheless, the use of metformin in patients with CKD remained contraindicated until 
recently. In April 2016, the US FDA revised the labeling of metformin and approved its 
use in patients with mild-moderate renal impairment (13) based on the eGFR status. 
Currently, metformin is contraindicated only in patients with an eGFR below 30 
mL/minute/1.73 m2. This expands the patient population (i.e., patients with stages 1 to 3 
of CKD) who could benefit from metformin (13). 
 Although the exact mechanisms through which metformin exerts its beneficial 
action are yet to be fully understood, a majority of reports link metformin’s therapeutic 
effects to its ability to activate AMP-activated protein kinase (AMPK) signaling (14-17). 
Nonetheless, emerging evidences also suggest for AMPK-independent actions of 
metformin. For instance, Ben Sahra et al. (2011) showed that the anti-proliferative effects 
of metformin in prostate cancer is AMPK-independent, and was mediated through p53 
and REDD1 (regulated in development and DNA damage responses 1) axis (18). 
Similarly, Kelly et al. (2015) reported that metformin inhibited reactive oxygen species 
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(ROS) production in macrophages in an AMPK-independent manner (19). The multiple 
beneficial effects of metformin therapy paired with its poorly characterized mechanism of 
action necessitates investigation of its therapeutic potential and the mechanistic pathways 
involved also in non-diabetic states such as CKD.  	
1.3. FACTORS CONTRIBUTING TO ALBUMINURIA AND CKD 
1.3.1. Diabetes Mellitus 
Diabetes mellitus is a metabolic condition characterized by an insufficient insulin 
production or signaling resulting in continuously elevated glucose levels. Proteinuria was 
first identified in diabetes mellitus patients in the late 18th century, but an association 
between the two was proven only later (20). In the 1950s, kidney disease was identified 
as one of the most prominent complications of diabetes. Furthermore, about 50% of 
patients suffering from diabetes for more than 20 years developed CKD (20). Presently, 
diabetes is considered as a major risk factor for the development of CKD worldwide (20). 
Moreover, in terms of morbidity and mortality rates, diabetic nephropathy is classified as 
one of the most serious long-term complications of diabetes. The most prominent 
histologic changes observed in the renal glomeruli of patients with diabetes are: 
thickening of glomerular basement membrane (GBM), expansion of the mesangium, and 
glomerular sclerosis (21). The sum of these three morphological changes leads to 
extracellular matrix accumulation and proteinuria (21). 
Different signaling pathways contribute to the histologic changes and the onset of 
nephropathy in patients with diabetes (7, 22). For instance, high glucose exposure in 
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glomerular mesangial cells was reported to increase the levels of angiotensin II (Ang II), 
a vasoactive peptide implicated in the pathogenesis of diabetic nephropathy (22). Studies 
suggest that hyperglycemia added to the increase in Ang II expression in the kidney 
triggers a multitude of intracellular signaling cascades, such as the polyol  (23) and the 
reactive oxygen species pathways (24) in diabetes patients. The sum of the 
aforementioned signaling processes triggers the Janus kinase/signal transducers and 
activators of transcription (JAK/STAT) signaling pathway in glomerular mesangial cells, 
eventually intensifying cell proliferation and growth, thus, leading to proteinuria and 
nephropathy (22). 
1.3.2. Hypertension 
The association between hypertension and renal injury is complex and 
multifactorial (25). For instance, different studies explained the causative relation 
between elevated blood pressure and CKD through the observed increase in the 
intraglomerular pressure, which leads to increased glomerular filtration and glomeruli 
injury. Consequently, the ultrafiltration increases, which in conjunction with altered 
glomerular membrane permeability causes an abnormal leakage of protein into the urine, 
i.e., proteinuria (25).  
Apart from its effects on the modulation of blood pressure, a direct association 
between the renin-angiotensin system (RAS) and the development and progression of 
renal injury is well documented (26). In particular, in cases where RAS was 
inappropriately triggered, a significant elevation in the intrarenal Ang II levels was noted 
(27). Ang II is then sequestered into the renal interstitial fluid and the proximal tubular 
compartments (27), resulting in the activation of the tubular angiotensin II type 1 (AT1) 
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receptors in the zona glomerulosa of the adrenal cortex. Stimulation of AT1 receptors 
triggers the production of mineralocorticoids and reactive oxygen species (ROS) (28). 
Increased ROS production was reported to activate mitogen-activated protein kinases 
(MAPK) and extracellular signal–regulated kinases (ERK), which together stimulate 
transforming growth factor-beta (TGF-β)/Smad pathway. This eventually leads to 
epithelial-to-mesenchymal transition (EMT) in proximal tubular epithelial cells and 
contributes to the development and progression of CKD (29). 
1.4. CELLULAR TRANSPORTATION AND FATE OF ALBUMIN 
Albumin, the most prominent plasma protein in mammals, is constituted of three 
homologous domains (I, II and III). Each homologous domain is composed of two sub-
domains: sub-domain A - comprised of six helices and sub-domain B - comprised of 4 
helices (30).  The domain-based structure of albumin facilitates its binding to a wide 
range of molecules, thereby allowing albumin to function as a plasma carrier and protein 
transporter. Additionally, albumin plays a major role in the regulation osmotic pressure 
by controlling the distribution of body fluids’ within the vasculature and across tissues 
(31). 
On a cellular level, albumin is transported into the cells by endocytosis via 
clathrin-dependent or independent pathways, where small vesicles are formed to facilitate 
albumin uptake (30). The exact mechanism responsible for albumin internalization is 
highly dependent on the cell type. For instance, in human skin fibroblasts and endothelial 
cells, albumin is taken up via caveolae-mediated endocytosis (30). On the other hand, in 
kidney cells, internalization of albumin is triggered by its binding to the low-density 
lipoprotein membrane receptor megalin, which functions through clathrin-dependent 
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process (32). Following its uptake, the intermediary pathways and the final target of 
albumin in many cells are yet to be determined. In kidney, albumin uptake and its fate are 
well-characterized in Madin-Darby kidney cell line (MDCK). Further to megalin-
mediated endocytosis, the clathrin-coated pits deliver albumin to early and late 
endosomes. The degradation process is then initiated by the transport of albumin 
containing endosomes to lysosomes in which albumin gets degraded to amino acids and 
recycled for various cellular processes such as energy metabolism and protein synthesis 
(30). 
 1.5. AMP-ACTIVATED PROTEIN KINASE (AMPK): STRUCTURE, 
FUNCTION AND REGULATION  
AMP-activated protein kinase (AMPK) is an intrinsic energy sensor that 
coordinates the intricate balance between energy production and expenditure in all 
eukaryotic cells. The structure of AMPK was characterized as a heterotrimeric complex 
with one catalytic (α) and two regulatory (β and γ) subunits (33). Owing to its vital role 
in the maintenance of cellular homeostasis, it is phylogenetically conserved across 
eukaryotes. In mammalian cells, seven genes - two isoforms each of the α and the β 
subunit, and three isoforms of the γ subunit - with 12 distinct heterotrimeric combinations 
were found to play a major role in the control of AMPK (34). Typically, the N-terminal 
of the α subunit is comprised of a serine/threonine kinase domain that is only activated 
subsequent to phosphorylation with a variety of upstream kinases (34). The regulatory 
adenine nucleotide-binding sites, which serve as cellular energy sensor, are located on the 
γ subunits. The catalytic binding site (CBS) motif, which is composed of four tandems 
repeats, is the main composition of the adenine-binding site. Different combinations of 
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these repeats form four adenine nucleotide-binding clefts, namely, site 1 to 4 (35). Site 1 
and 3 are thought to be the most essential as they are the binding clefts for AMP, ADP, 
and ATP, and act as cellular energy sensors (Figure 1.3). 
 
 
 
Figure 1.3. AMPK Structure and Its Regulation Via Phosphorylation. In the presence of 
AMP threonine 172 gets phosphorylated, increasing the AMPK activity by 100 Folds. 
AMPK, AMP activated Kinase. 
 
 
The core function of AMPK is dependent on cellular energy levels, which is 
determined by the concentration of AMP over ATP and the resultant AMP/ATP ratio 
(36). An increase in the AMP concentration coupled with a decrease in the ATP level 
leads to binding of AMP to the catalytic subunit of AMPK and its subsequent 
phosphorylation at Thr172. Further to the AMP/ATP ratio increase, AMPK activation 
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takes place through three main mechanisms (37). The first pathway takes place via a 
direct allosteric activation. The second mechanism is initiated by the binding of AMP to 
the catalytic loop allowing its phosphorylation via one of the upstream AMPK kinases 
(38). Following its phosphorylation, a 100-fold increase in the AMPK activity is noted 
(39). Furthermore, at least two upstream kinases are known to increase the AMPK 
activity by up to a 1,000-fold (40). The final pathway functions mainly through the 
activation of a protein phosphatase that inhibits the dephosphorylation of Thr172 (35). 
The concerted actions of the three pathways make the system exquisitely sensitive to 
even minimal changes in AMP levels. Conversely, these three mechanisms are inhibited 
in cases where the AMP/ATP ratio is decreased. 
 1.6. EXPRESSION OF AMPK IN THE RENAL SYSTEM AND ITS ROLE IN 
RENAL HOMEOSTASIS  
AMPK expression in the renal system was best characterized in rat models (41). 
The predominantly expressed AMPK subunits in the kidneys were found to be α1, β2, 
γ1, and γ2 (41). Immunostaining of kidneys for AMPK by Fraser et al. (2005) revealed 
that the strongest expression of AMPK occurs at the cortical thick ascending limbs, the 
macula densa and the basolateral surface of collecting ducts (42). The localization of 
AMPK within the renal system served as an initial step in determining its role in renal 
homeostasis.  
Disproportionate to their size, kidneys receive 20 to 25% of cardiac output and 
accounts for about 7% of total oxygen consumption. This high perfusion rate and energy 
consumption by the kidneys in comparison to their tissue mass could be justified by their 
role in active tubular reabsorption of considerably large quantities of sodium and other 
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ions. Initial studies showed that tubular sodium transport and tubular respiration are 
closely related; nonetheless, the pathways by which the coupling takes place were yet to 
be defined. Recent studies reveal that AMPK plays a crucial role in the regulation of 
several ion transport proteins (41, 43). However, the exact pathway by which AMPK 
maintains a firm coupling between energy metabolism and tubular transport is yet to be 
known. 
1.7. AMPK AND CKD: SPECULATED PATHWAYS  
1.7.1 AMP-activated protein kinase (AMPK) 
Several studies have attempted to determine the link between these upstream 
kinases and the phosphorylation of AMPK (44, 45). Hitherto, two kinases - the tumor 
suppressor gene (LKB1) and Ca2+/calmodulin-dependent protein kinase (CaMKKβ) - 
were identified as the major upstream signal for activation of AMPK (44, 45). Both of 
which were shown to cause an AMP-independent phosphorylation of threonine-172 
residue in AMPK-α subunit (46).   
A study by Woods et al. (2003) in HeLa S3 and G361 cell lines revealed a strong 
correlation (Pearson correlation coefficient of 0.945, p< 0.005) between LKB1 levels and 
AMPK activity (46). Contrary to these findings, a study by Hurley et al. (2005) 
demonstrated that the phosphorylation of AMPK further to cellular stimulation with 
ionomycin and 2-DG was not impaired in LKB1-/- cells as compared with LKB1+/+ cells 
(46). In fact, the LKB1 deficient cells showed a paradoxical increase in the 
phosphorylation and activation of AMPK, which can be further increased in the presence 
of calcium ionophores. Pharmacologic inhibition of CaMKKβ and silencing with 
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isoform-specific siRNAs proved that CaMKKβ is essential for AMPK phosphorylation 
(47). A variety of studies were conducted to identify other protein kinases responsible for 
AMPK phosphorylation. Three kinases were recently identified in yeast, and evidence of 
a third AMPK kinase (Tak1) in mammalian cells was reported. Nonetheless, the 
physiological significance of these kinases is yet to be determined (48). 
Metformin, a commonly used medication for the management of type II diabetes, 
is known to exert its action through activation of AMPK. A study by Hawley et al. (2002) 
showed that exposure of cells to metformin leads to phosphorylation of the Thr-172 
residue on the catalytic (α) subunit of AMPK. In AMPK-α1 knockout animal models, p-
AMPK levels were found to be blunted despite metformin treatment (49). Conversely, 
administration of metformin to mice for three days showed an elevation in p-AMPK 
levels in the whole-body (49). 
 1.7.2. Mammalian target of rapamycin (mTOR) 
 
 The mammalian target of rapamycin (mTOR) pathway regulates an array of cellular 
processes ranging from transcription and protein synthesis to cell growth and 
proliferation (50).  So far, two distinct protein complexes of mTOR were identified: 
mTOR complex 1 (mtorc1) and mTOR complex 2 (mTORC 2). Both protein complexes 
are thought to have the subunits mTOR, mlst8, and deptor in common. Nonetheless, the 
rapamycin-insensitive companion of tor (rictor), mammalian stress-activated protein 
kinase (msin1) and proline-rich protein 5 (protor) were only identified in mTORC 2 (50). 
In regards to their function, both mtor complexes phosphorylate a variety of proteins that 
are involved in regulation of cellular function. For example, mtorc1 stimulates the 
initiation of cap-dependent translation through its two downstream targets: eif4e-binding 
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proteins (4e-bps) and s6 kinases (s6k1 and s6k2), leading to cell growth and proliferation. 
Whereas mtorc2 phosphorylates akt, sgk1, and pkc, and is responsible for cell survival 
and cytoskeletal organization (51).	
Multiple signaling pathways control the activity of mTORC in cells (Figure 1.4). 
For instance, a study by Inoki et al. (2003) in HEK293 cells demonstrated that ATP 
depletion activates AMPK and increases the activity of tuberous sclerosis complex 2 
(TSC2) (52). The study also revealed that overexpression of TSC2 reduces the 
phosphorylation of mTORC1 targets: 4E-BPs and S6Ks, and thereby decreasing the 
activity of mTOR (52).  
Similarly, a study by Takiar et al. (2011) in canine kidney cells revealed that 
activation of AMPK via metformin led to time-dependent inhibition of the downstream 
targets of mTOR - ribosomal S6 kinase (S6K) and p70 subunit (p70S6K). Furthermore, a 
dose-dependent decrease in cell proliferation was observed with metformin treatment in 
the wild-type cells but not in the AMPK-deficient cells, indicating that the inhibitory 
effects of metformin on mTOR are mediated via AMPK activation (53).    
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Figure 1.4.  Signaling Pathways Linking AMPK and mTOR. Energy starvation triggers 
the phosphorylation of LKB1 and increases the expression of CaMKK. This stimulates 
the phosphorylation of AMPK and increases the expression of mTORC1 regulatory 
protein TSC-2. TSC-2 inhibits mTORC activation, thereby inhibiting 4EBP-1 and 
P70S6K. LKB1, Liver kinase B1; CaMKK, Ca2+/calmodulin-dependent protein kinase 
kinase; TSC-2, Tuberous Sclerosis Complex 2; mTORC1, Mammalian target of 
rapamycin complex 1; 4EBP1, Eukaryotic translation initiation factor 4E-binding protein 
1; P70S6K, Ribosomal protein S6 kinase. 
 
 
1.7.3. Endoplasmic Reticulum (ER) Stress 
The endoplasmic reticulum (ER) is the chief organelle responsible for protein 
folding and lipid synthesis. Furthermore, the ER functions as a sensor and a regulator of 
cellular homeostasis. In cases of cellular stress, unfolded proteins accumulate in the ER 
and activate three main cellular sensors: inositol-requiring enzyme-1α (IRE-1α), RNA-
dependent protein kinase-like ER kinase (PERK), and transcription factor 6 (ATF6). 
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Activation of these sensors is known as the unfolded protein response (UPR), which is an 
adaptive mechanism aimed at restoration of cellular homeostasis. ER stress ensues when 
UPR fails to restore homeostasis (54). 
AMPK plays a major role in sensing cellular stress and restoring cellular 
homeostasis in response to stress (33). A study by Dong et al. (2010) revealed that 
AMPK activation confers cytoprotection through stimulation of cell survival and 
inhibition of inflammatory and oxidative response in cells (55). Xi et al. (2013) 
demonstrated that ER stress induced with 2-deoxyglucose and tunicamycin activates 
AMPK via Ca2+- calmodulin-dependent protein kinase kinase-β (CaMKKβ) and 
consequently stimulates autophagy. This study highlights the function of AMPK as an 
ER stress sensor (56). Alternatively, Jia et al. (2015) showed that activation of AMPK by 
N(1)-(β-d-Ribofuranosyl)-5-aminoimidazole-4-carboxamide (AICAR) attenuates ER 
stress via inhibition of the phosphorylation of IRE-1α and PERK (54). Furthermore, the 
knockdown of AMPK in the above model diminished the protective effects of AICAR 
against ER stress (54). Similarly, a study by Kim et al. (2015) showed that AMPK 
activation by metformin suppressed tunicamycin and thapsigargin-induced ER stress 
(57). Moreover, when AMPK was pharmacologically inhibited using Compound C, the 
effect of metformin was abolished; further proving that the reduction of ER stress 
observed with metformin is mediated via AMPK activation (57).  
1.7.4. Autophagy  
Autophagy, a highly conserved process across eukaryotes, encompasses all 
pathways leading to the delivery of cytoplasmic material to the lysosome for recycling or 
degradation (58). In general, three different classes of autophagy (macro-, micro- and 
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chaperone-mediated) were identified in eukaryotes. The most studied class is the 
macroautophagy, in which sequestering of a minute portion of the cytoplasm takes place 
through an isolation membrane known as phagophore, which sequentially form 
autophagosomes. Further fusion of autophagosomes with lysosome leads to the formation 
of autolysosome and results in cargo degradation and recycling. In microautophagy, an 
inward invagination of the lysosome membrane takes place to engulf small components 
of the cytoplasm. The third category of autophagy, which is mediated by chaperones, is 
the only type of autophagy that does not involve membrane restructuring. Nonetheless, a 
direct translocation of proteins across lysosomal membrane occurs during this process 
(58). 
As mentioned earlier, AMPK plays a central role as a cellular energy sensor, 
while mTOR, particularly mTORC1 regulates nutrient signaling and cellular proliferation 
(52). The link between mTOR and autophagy is thought to be mediated through the 
mTORC1-aminoacid signal (59). The presence of a significant concentration of amino 
acids leads to the activation of the Rag guanosine triphosphatases (GTPases), which 
favors mTORC1 translocation to its activation site on the lysosomal surface. Studies 
indicate that the vacuolar H+-adenosine triphosphatase ATPase (v-ATPase) is necessary 
for amino acids to activate mTORC1 (59). The translocation of mTORC1 to the 
lysosomes plays a crucial role in the regulation of autophagy. In non-starving conditions, 
the phagophore formation is suppressed through the attenuation of a serine/threonine-
protein kinase UNC-51-like kinase 1 (ULK1) and autophagy-related gene 13 (ATG13) 
(60). Conversely, during cellular starvation or AMPK activation, an inhibition of 
mTORC1 takes place, which allows phagophore formation and the subsequent fusion of 
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autophagosomes with lysosomes to enable protein digestion (61). 
Emerging evidence supports a linear relationship between AMPK and ULK1. Using 
bioinformatics, Egan et al. (2011) identified four potential AMPK-sensitive 
phosphorylation sites on ULK1 (62). Furthermore, treating cells with phenformin 
confirmed the phosphorylation of the described site (62). Consistent with these findings, 
Kim et al. 2011 showed that glucose starvation (a strong stimulus for AMPK activation) 
activates ULK1 in cells. Whereas cellular exposure to an AMPK inhibitor prevented 
ULK1 activation and attenuated autophagy (Figure 1.5) (61).   
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Figure 1.5. AMPK mediated autophagy. Energy starvation triggers the phosphorylation 
of AMPK. The increase in phosphorylated AMPK levels stimulates the activation of 
mTOR regulatory protein TSC-2 and increases the phosphorylation of ULK1. Increased 
ULK1 activity in conjunction with the inhibition of mTORC1 stimulates autophagy. 
ULK1: UNC-51-like kinase 1. 
 
 
To further explore the cytoprotective effects of autophagy, Declèves et al. (2014) 
and Wei et al. (2015) investigated the mechanism by which autophagy promotes cell 
survival in kidney ischemia-reperfusion model (63) and cisplatin-induced acute kidney 
injury model (64) respectively. Intriguingly, in both models, AMPK activation inhibited 
mTOR pathway and induced autophagy, while chemical inhibition or knockdown of 
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AMPK blocked autophagy and resulted in DNA damage and cellular apoptosis (63, 64).  
 1.7.5. Epithelial-to-Mesenchymal Transition (EMT) 
Epithelial-to-mesenchymal transition (EMT) is characterized by a defined 
sequence of three major events in which epithelial cells lose cell-cell adhesion (1), 
undergo cytoskeletal reorganization (2), and transcriptional reprogramming (3) to acquire 
a mesenchymal phenotype. The loss of cell-cell adhesion during EMT allows the 
epithelial cells to get released from the surrounding cells. Secondly, the restructuring of 
the cytoskeleton enables the cells to move across the extracellular matrix (ECM). These 
two processes in conjunction with induction of transcriptional reprogramming enables the 
epithelial cells to transform into mesenchymal phenotype (65). EMT is essential during 
embryonic period as it allows organ differentiation and development (66). EMT is 
systematized through cell-cell and cell-ECM interactions (66). Disturbances to the 
coordination between the aforementioned processes lead to the initiation of spontaneous 
and cell-autonomous EMT, thereby increasing the production of mesenchymal cells and 
disrupting the epithelial tissue, eventually perpetuating alterations in the cellular 
architecture (65, 66).  
A prominent pathological feature of CKD is the replacement of normal renal 
structures by fibrotic tissues in both the glomeruli and the tubulo-interstitial space (67). 
Studies by Iwano et al (2002) using transgenic mice with a reporter gene on proximal 
tubular epithelial cells revealed that the origin of more than 35% of fibroblast-specific 
protein-1 (FSP1) positive fibroblast is renal proximal tubules. This study highlighted the 
significant impact EMT has on the development and progression of CKD (68). Using a 
similar cell lineage tracking technique, studies conducted by Zeisberg et al. (2008) and Li 
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J et al. (2009) showed that a significant proportion of interstitial fibroblasts are originated 
from capillary endothelia, i.e., endothelial to mesenchymal transition (EndoMT). Taking 
into account that endothelial cells represent a specialized type of epithelial cells, EndoMT 
is therefore, a form of EMT occurring in injured renal tissues (69, 70). Consistent with 
these findings, studies in different animal models of diabetic (71) and obstructive 
nephropathy (72) showed similar findings. Additionally, studies in human renal biopsies 
have shown that the expression of vimentin (a mesenchymal protein) and FSP1 within 
tubular cells correlates with the progression of renal injury in various types of kidney 
diseases (73, 74). Together, these studies provide substantial evidence for the 
involvement of EMT in the pathogenesis of CKD. 
A strong correlation between AMPK inactivation and induction of EMT was 
reported in multiple organs including hepatic (75), cardiac (76) and renal systems (77). 
For instance, Lee et al. (2013) showed that activation of AMPK using metformin in 
human proximal tubular cells blocked ROS generation through induction of heme 
oxygenase-1 and an endogenous antioxidant thioredoxin, thereby suppressing EMT. 
Furthermore, ablation of AMPK signaling by chemical inhibition and small interference 
RNA-mediated silencing hindered the effects of metformin, thereby proving the 
beneficial effects AMPK activation has in attenuating tubulointerstitial fibrosis (78). 
Alternatively, knockdown of AMPKα2 in a murine model of unilateral ureteral 
obstruction (UUO) led to the up-regulation of pro-fibrotic factors such as β-catenin and 
Smad3 and concomitant induction of EMT and renal fibrosis. On the other hand, 
promoting AMPKα Thr172 phosphorylation in the kidney attenuated EMT in renal 
tubular epithelia, and mitigated renal injury induced by UUO (77). Similar findings were 
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also reported by Wang et al. (2016) in a rat model of acute renal ischemia-reperfusion 
(79). Altogether, these studies support the fact that AMPK activation could serve as a 
therapeutic strategy to attenuate tubulointerstitial fibrosis and EMT in the kidney.  
1.7.6. Apoptosis  
Apoptosis (also known as programmed cell death) is defined as a rigorously 
controlled form of cell death essential for healthy proliferation and development of 
multicellular organisms. Defective apoptosis can result in abnormal development and 
pathogenesis (80).  
AMPK is thought to be an anti-proliferation kinase; this is due to its association 
with tumor suppressor genes (LKB1 and TSC2). The activation of AMPK takes place 
through its upstream stimulating kinase LKB1, which links the regulation of cellular 
metabolism to cell proliferation and growth (81). Several studies reported that LKB1 
stimulates AMPK and thus serves as an AMPK kinase (AMPKK) (82, 83). In addition, 
studies from two independent groups Hawley et al. (2005) and Hurley et al. (2005) 
revealed that Ca2+/ calmodulin-dependent protein kinase kinase (CaMKK) also acts as an 
upstream activator of AMPK (45, 46). In this regard, a variety of studies over the last 
decade demonstrated the anti-apoptotic effects of activated AMPK in mammalian cells 
(57, 82, 84).  
Studies by Stefanelli et al. (1998) and Durante et al. (1999) revealed that 
activation of AMPK with AICAR protects rat thymocytes and fibroblasts from apoptosis 
induced by dexamethasone (84) and serum starvation (85) respectively. Furthermore, 
Kim et al. (2011) showed that specific activation of AMPK using A769662 ameliorates 
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palmitate-induced ER stress, tau hyperphosphorylation and apoptosis in neuroblastoma 
cells (86). 
In consistence with the aforementioned findings, studies conducted in the renal 
system also support the inhibitory effects AMPK activation has on apoptosis. In a recent 
study by Han et al., specific deletion of the upstream kinase LKB1 in the renal distal 
tubules and the resultant diminution in AMPK signaling in mice induced energy 
deficiency marked by reduced fatty acid oxidation and glycolysis, and increased cellular 
apoptosis. Pharmacological activation of AMPK with A769662 in LKB1-deficient cells 
improved fatty acid oxidation and lessened apoptosis (87). Additionally, exposure of 
podocytes to high glucose levels led to programed cell death through blockade of AMPK 
phosphorylation, and increase in the expression of NADPH oxidase (a pro-oxidant 
enzyme) and phosphorylation of its downstream target p53. Restoration of AMPK 
phosphorylation reversed the detrimental effects of high glucose and promoted cell 
survival (88). Furthermore, glomeruli isolated from diabetic mice revealed a major 
decrease in phosphorylated AMPK levels and pharmacological activation of AMPK 
exerted a renoprotective effect via decreasing NADPH oxidase levels (88). Similarly, Li 
et al. (2015) reported reduced levels of AMPK and hypoxia-inducible factor-1 (HIF-1α) 
and accelerated apoptosis in rat kidneys subjected to subtotal nephrectomy (STN), a 
model of CKD (89). Intriguingly, activation of HIF-1α induced AMPK in the kidney and 
inhibited apoptosis (89). In vitro studies demonstrated that the anti-apoptotic effects of 
HIF-1α were lost when AMPK is inhibited in cells. Thus, it is clear that AMPK 
activation exerts cytoprotective effects on various organs including the kidney.   
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Thesis Objectives 
 
Increased albumin excretion, commonly referred to as proteinuria, is strongly 
associated with the development and progression of chronic kidney disease (CKD). 
Proteinuria is thought to induce endoplasmic reticulum (ER) stress, consequently 
triggering AKT pathway and inhibiting AMP-activated kinase (AMPK). The inactivation 
of AMPK was found to trigger mTOR (mammalian target of Rapamycin) pathway, 
subsequently inhibiting autophagy and inducing epithelial-to-mesenchymal transition 
(EMT), eventually accelerating renal cell apoptosis and contributing to CKD. AMPK 
activation may potentially reverse the aforementioned pathways, and therefore, may 
protect against CKD.  
 
The objectives of this study are:  
1) To standardize and characterize an in vitro model of albumin-induced ER stress and 
renal cell injury,  
2) To investigate the effects of metformin (an AMPK activator) on ER stress, AKT, 
mTOR, EMT, autophagy and apoptosis in the established in vitro model of albumin-
induced renal cell injury, and  
3) To dissect the AMPK- and non-AMPK mediated effects of metformin in the 
established in vitro model using an AMPK inhibitor Compound C. 
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Chapter 2: Methods 
 
 2.1. CELL CULTURE 
Normal Rat kidney cells (NRK-52E; Health Protection Agency, UK) were 
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM; Life Technologies, UK) 
complemented with 5% fetal bovine serum (FBS), 1% L-Glutamine and 1% 
Penicillin/Streptomycin and incubated at 37°C in 5% CO2 atmosphere. Trypan blue 
exclusion assay was performed regularly to monitor the viability of cells.  
 
2.2. STANDARDIZATION OF AN IN VITRO MODEL OF ALBUMIN-INDUCED 
RENAL CELL INJURY  
NRK-52E cells (a rat renal proximal tubule cell line) grown to 60% confluency 
were divided into two main groups based on the FBS concentration (1% FBS vs. 5% 
FBS); each of the groups were further divided into six sub-groups based on the albumin 
treatment concentration (as shown in Figure 2.1): 
1. Control (Vehicle-treated) 
2. 1 mg/ml Albumin treated 
3. 5 mg/ml Albumin treated 
4. 10 mg/ml Albumin treated 
5. 15 mg/ml Albumin treated 
6. 30 mg/ml Albumin treated 
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After exposure of cells to albumin for 48, 72 and 120 hours, the following parameters 
were assessed as described in the Table 2.1.  
 
 
Table 2.1. 
Parameters assessed in NRK-52E cells following 48 and 72 h albumin treatment  
Parameter assessed Protein measured Time point  
AMPK pathway Phospho-AMPK and total-AMPK 
48 hours mTOR pathway Phospho-4EBP-1 and Phospho-P70S6K 
AKT pathway Phospho-AKT and total-AKT 
ER Stress GRP78 and CHOP 
72 hours 
Epithelial-to-Mesenchymal 
Transition (EMT) 
α-SMA and E-cadherin 
Autophagy Phospho-ULK1 and LC3-II 
Apoptosis  Caspase 12 and Caspase 3 
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Figure 2.1. Experimental design for standardization of an in vitro model of albumin-
induced renal cell injury using rat renal proximal tubular (NRK-52E) cells. 
 
 
2.3. EVALUATION OF THE EFFECTS OF METFORMIN AGAINST ALBUMIN-
INDUCED RENAL INJURY 
NRK-52E cells were grown to 60% confluency and divided into six treatment 
groups: 
1. Control (Vehicle-treated) 
2. 1 mM Metformin treated 
3. 10 mg/ml Albumin treated 
4. 10 mg/ml Albumin +1 mM Metformin treated 
5. 15 mg/ml Albumin treated 
6. 15 mg/ml Albumin +1 mM Metformin treated  
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After exposing the cells to metformin for 48 and 72 hours, the following parameters were 
assessed as described in the Table 2.2.  
 
 
Table 2.2. 
Parameters assessed in NRK-52E cells following 48 and 72 h albumin and metformin co-
treatment 
Parameter assessed Protein measured Time point 
AMPK pathway Phospho-AMPK and total-AMPK 
48 hours mTOR pathway Phospho-4EBP-1 and Phospho-P70S6K 
AKT pathway Phospho-AKT and total-AKT 
ER Stress GRP78 and CHOP 
72 hours 
Epithelial-to-Mesenchymal 
Transition (EMT) 
α-SMA and E-cadherin 
Autophagy Phospho-ULK1 and LC3-II 
Apoptosis  Phospho-SAPK/JNK, Caspase 12 and 
Caspase 3 
 
  
 
 
		 29	
 
Figure 2.2. Experimental design for Evaluation of the effects of Metformin against 
albumin-induced renal injury. 
 
 
2.4. IDENTIFICATION OF THE AMPK-MEDIATED AND NON-AMPK 
MEDIATED EFFECTS OF METFORMIN AGAINST ALBUMIN-INDUCED 
RENAL INJURY 
2.4.1. Concentration-Response Studies for Compound C 
NRK-52E cells were grown to 60% confluency and divided into treatment groups 
as follows: 
1. Control 
2. Metformin (1 mM) treated 
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3. Compound C (0.05, 0.1, 0.5, 1, 3, 5, 10, 20 or 40 µM) treated 
4. Metformin (1 mM) + Compound C (0.05, 0.1, 0.5, 1, 3, 5, 10, 20 or 40 µM) 
treated 
After exposing the cells to metformin for 48 and 72 hours, the following parameters were 
assessed as described in the Table 2.3. 
 
 
Table 2.3.  
Parameters assessed in NRK-52E cells following 48 h of compound C treatment 
Parameter assessed Protein measured Time point 
AMPK pathway Phospho-AMPK and total-AMPK 
48 hours 
mTOR pathway Phospho-4EBP-1  
 
 
2.4.2. Effects of Compound C-mediated AMPK inhibition on metformin-mediated 
outcomes  
NRK-52E cells were grown to 60% confluency and divided into eight treatment 
groups as follows. 
1. Control 
2. Albumin (10 mg/ml) 
3. Metformin (1 mM)  
4. Albumin (10 mg/ml) + Metformin (1 mM) 
5. Compound C (0.5 µM) 
		 31	
6. Albumin (10 mg/ml) + Compound C (0.5 µM) 
7. Metformin (1 mM) + Compound C (0.5 µM) 
8. Albumin (10 mg/ml) + Metformin (1 mM) + Compound C (0.5 µM) 
After exposing the cells to metformin for 48 and 72 hours, the following parameters were 
assessed as described in the Table 2.4.  
 
 
Table 2.4.  
Parameters assessed in NRK-52E cells following 48 and 72 h albumin, metformin and 
compound C treatment 
Parameter assessed Protein measured Time point 
AMPK pathway Phospho-AMPK and total-AMPK 
48 hours 
mTOR pathway Phospho-4EBP-1 
ER Stress GRP78 and CHOP 
72 hours 
Epithelial-to-Mesenchymal Transition 
(EMT) 
α-SMA  
Autophagy LC3-II 
Apoptosis  Caspase 12 and Caspase 3 
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Figure 2.3. Experimental design to identify the AMPK mediated effects of metformin 
using Compound C. 
 
 
 2.5. GENERAL METHODS 
2.5.1. Western Blotting 
Western blotting was used to determine the expression of proteins of interest 
following drug treatments. Cells were seeded onto 6-well plates, and treated as per 
treatment protocol. At the endpoint, cells were lysed in 60 mM Tris pH 6.8 and 2% SDS 
lysis buffer and collected. Samples were sonicated for 15 seconds at 5 second intervals 
and centrifuged at 16,000xg for 15 minutes at 4°C. Protein concentrations were 
quantified using Bicinchonic acid (BCA) Protein Assay Kit (Pierce, USA) as per 
manufacturer’s protocol. 12% and 15% sodium dodecyl sulfate-polyacrylamide gels 
(SDS-PAGE) were loaded with 40-50 µg of proteins. Electrophoresis conditions were set 
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at 60 volts for 20 minutes followed by 150 volts for 90 minutes. Thereafter, proteins were 
transferred from the gel to polyvinylidene fluoride (PVDF) membranes at 100 volts for 
90 minutes via wet transfer technique.  
Blockade of non-specific binding was ensured by incubating PVDF membranes 
with either 5% skimmed milk or bovine serum albumin (BSA) diluted in Tris-buffered 
saline (TBS) - depending on the protein of interest - for 1 hour at room temperature. 
Primary antibodies diluted in TBS containing 3% skimmed milk or BSA at specific 
concentrations listed in the Table 2.5 were added to the membrane and incubated 
overnight at 4°C. The next day, membranes were washed using 0.1% Tween-20 
containing TBS (TBS-T) for 3 times at 10 minute intervals. Secondary antibodies of 
either horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (1:10,000; Abcam, 
UK) or HRP-conjugated goat anti-rabbit IgG (1: 20,000; Abcam, UK) (diluted in TBS) 
were added to the membrane for 1 hour at room temperature. To visualize the protein 
bands, Optiblot ECL detection kit (Abcam, UK) was added to the membranes, and the 
images were captured using FluroChem M imaging system (Protein Simple, USA). The 
protein bands were analyzed using NIH ImageJ 1.48V software, and the densitometry 
values were normalized to beta-actin (a loading control) and expressed as folds of control 
(90).  
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Table 2.5.  
Primary and secondary antibodies used in the study 
Protein Primary Antibody Secondary 
Antibody 
Source  
Phospho-AMPKα  Rabbit Monoclonal 
Antibody (Thr172) 
(D79.5E), 1:1000 
Goat anti-rabbit 
(GAR): HRP 
conjugated 	
Cell Signaling 
Technology, 
Netherlands 
AMPKα Rabbit Monoclonal 
Antibody, 1:1000 
Goat anti-rabbit 
(GAR): HRP 
conjugated  
Cell Signaling 
Technology, 
Netherlands 
AKT1  
 
Rabbit Monoclonal 
antibody (phospho 
S473) [EP2109Y], 
1:1000 
Goat anti-rabbit 
(GAR): HRP 
conjugated  
Abcam, UK 
Anti-AKT1  
 
Rabbit Monoclonal 
antibody [Y89], 
1:1000 
Goat anti-rabbit 
(GAR): HRP 
conjugated  
Abcam, UK 
Phospho-p70 S6 
Kinase  
 
Rabbit Monoclonal 
antibody, (Thr389) 
(108D2), 1:1000 
Goat anti-rabbit 
(GAR): HRP 
conjugated  
Cell Signaling 
Technology, 
Netherlands 
Phospho-4E-BP1  
 
Rabbit Monoclonal 
antibody, 
Goat anti-rabbit 
(GAR): HRP 
Cell Signaling 
Technology, 
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(Thr37/46) (236B4), 
1:1000 
conjugated  
 
Netherlands 
Phospho-eIF2α  
 
Rabbit Monoclonal 
antibody, (Ser51) 
(D9G8) XP®, 
1:1000 
Goat anti-rabbit 
(GAR): HRP 
conjugated  
 
Cell Signaling 
Technology, 
Netherlands 
GADD153 (CHOP)  Rabbit Monoclonal 
antibody (R-20), 
1:1000 
Goat anti-rabbit 
(GAR): HRP 
conjugated  
Santa Cruz, 
Germany 
 
GRP78/BiP  
 
Rabbit Polyclonal 
antibody, 1:1000 
Goat anti-rabbit 
(GAR): HRP 
conjugated  
Abcam, UK 
Alpha-Smooth 
Muscle Actin 
 
Mouse monoclonal 
antibody, 1:500 
Goat anti-mouse 
(GAM): HRP 
conjugated  
Abcam, UK 
Phospho-ULK1  
 
Rabbit Monoclonal 
antibody (Ser555) 
(D1H4), 1:1000 
Goat anti-rabbit 
(GAR): HRP 
conjugated  
Cell Signaling 
Technology, 
Netherlands 
ULK1  
 
Rabbit Monoclonal 
antibody, (D8H5), 
1:1000  
Goat anti-rabbit 
(GAR): HRP 
conjugated  
Cell Signaling 
Technology, 
Netherlands 
LC3B  
 
Rabbit Monoclonal 
antibody, 1:1000 
Goat anti-rabbit 
(GAR): HRP 
Cell Signaling 
Technology, 
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Caspase-3 
 
Rabbit Monoclonal 
antibody, 1:1000 
Goat anti-rabbit 
(GAR): HRP 
conjugated 
Abcam, UK 
β-Actin  
 
Rabbit Monoclonal 
antibody (13E5), 
1:1000 
Goat anti-rabbit 
(GAR): HRP 
conjugated 
Cell Signaling 
Technology, 
Netherlands 
 
 
2.5.2. Cell Viability Assay (MTT Assay) 
MTT assay was used to quantify cell viability following albumin treatment. The 
assay is based on the ability of mitochondrial dehydrogenases to reduce the yellow 
colored MTT reagent (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) to 
insoluble purple formazan crystals. The formed crystals were then solubilized in 
inorganic solvent and the intensity of the produced color was quantified using 
spectrophotometry. Following 72 hours of treatment, the old media was removed and 100 
µl of serum free media containing 0.5 mg/ml MTT reagent (Sigma Aldrich, M2128) was 
added to the plate and incubated at 37°C for 4 hours. Thereafter, the media was carefully 
aspirated and 50 µl of dimethylsulfoxide (DMSO) was added to solubilize the formazan 
crystals. Using a microplate reader, absorbance was then measured at 570 nm; the control 
conjugated Netherlands 
Caspase-12  
 
Rabbit Monoclonal 
antibody, 1:1000 
Goat anti-rabbit 
(GAR): HRP 
conjugated 
Abcam, UK 
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readings were set to 100% and treatment readings were expressed as a percentage of the 
control (91).  
2.5.3. Statistical Analysis 
A minimum of three independent experimental samples were obtained and tested 
for statistical significance. Values were expressed as Mean ± SEM. The data sets were 
tested for Gaussian distribution using normality and equal variance test. One-way 
ANOVA followed by post-hoc Tukey test was used for comparison of multiple groups. A 
P value of less than 0.05 was considered to be statistically significant. 
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 Chapter 3: Results 
3.1. STANDARDIZATION OF AN IN VITRO MODEL OF ALBUMIN-INDUCED 
RENAL CELL INJURY  
NRK-52E cells were exposed to various concentrations of albumin ranging from 
1 to 30 mg/ml in culture media with or without 5% fetal bovine serum (FBS) for 24 hours 
to 120 hours. Untreated cells were used as control. Cell injury was quantified using MTT 
assay.  
 
 3.1.1. Effect of Albumin on Renal Cell Injury Following 24 hours of Treatment  
No significant differences in cell injury were observed in albumin-treated groups 
following 24 hours of exposure in serum-free media or the 5% FBS containing media 
(Figure 3.1).  
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Figure 3.1. Effect of various concentrations of albumin on the viability of NRK-52E cells 
following 24 hours of treatment in serum-free media (A) and in media containing 5% 
FBS (B). Values were expressed as Mean ± SEM; n = 6. * p < 0.05 vs. Control. 
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 3.1.2. Effect of Albumin on Renal Cell Injury Following 48 hours of Treatment  
Under serum-free conditions, treatment with albumin had no prominent effect on 
the viability of NRK-52E cells (Figure 3.2A). Whereas, cells exposed to albumin in 
media containing 5% FBS showed a progressive decline in cell viability (Figure 3.2B). 
Furthermore, a statistically significant (P < 0.05) decrease in cell viability was noted in 
cells treated with 30 mg/ml of albumin as compared to the control.  
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Figure 3.2. Effect of various concentrations of albumin on the viability of NRK-52E cells 
following 48 hours of treatment in serum-free media (A) and in media containing 5% 
FBS (B). Values were expressed as Mean ± SEM; n = 6. *P < 0.05 vs. Control. 
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 3.1.3. Effect of Albumin on Cell Injury Following 72 hours of Treatment  
Intriguingly, NRK-52E cells exposed to albumin in serum-free or 5% FBS 
containing media for 72 hours showed no differences in cell viability (Figure 3.3).  
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Figure	3.3.	Effect	of	various	concentrations	of	albumin	on	the	viability	of	NRK-52E	cells	 following	 72	 hours	 of	 treatment	 in	 serum-free	 media	 (A)	 and	 in	 media	containing	5%	FBS	(B).	Values	were	expressed	as	Mean	±	SEM;	n	=	6.	*P	<	0.05	vs.	Control. 
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3.1.4. Effect of Albumin on Cell Injury Following 120 hours of Treatment  
Consistent with 24, 48 and 72 hours’ albumin treatment groups under serum-free 
conditions, cells exposed to albumin for 120 hours in serum-free media showed no 
differences in cell viability compared to control (Figure 3.4A). In contrast, cells exposed 
to albumin in 5% FBS containing media showed statistically significant decreases in cell 
viability in all albumin-treated groups as compared to the control (Figure 3.4B). 
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Figure 3.4. Effect of various concentrations of albumin on the viability of NRK-52E cells 
following 120 hours of treatment in serum-free media (A) and in media containing 5% 
FBS (B). Values were expressed as Mean ± SEM; n = 6. *P < 0.05 vs. Control. 
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3.1.5. Effect of Albumin on ER Stress Following 72 hours of Treatment 
Based on the findings from MTT assay, albumin treatments in media containing 
5% FBS was found to yield more consistent results as compared to those conducted in 
serum-free conditions. Therefore, all cell treatments were performed in media containing 
5% FBS. 
 
  Western blotting followed by densitometry was used to quantitate the expression 
of ER stress response proteins GRP78 and CHOP in NRK-52E cells subjected to 1 to 30 
mg/ml albumin in 5% FBS containing media for 72 hours. Our results revealed that the 
expression of GRP78 and CHOP was significantly increased (p < 0.05) in all albumin-
treated groups as compared to the control (Figure 3.5).   
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Figure 3.5. Effect of albumin on the expression of GRP78 and CHOP in NRK-52E cells 
following 72 hours of treatment. Upper panel (A) showing a representative western blot 
and the lower panel (B) showing the densitometry measurements normalized to β-actin. 
Values were expressed as Mean ± SEM; n = 3; *P < 0.05 vs. Control. 
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3.1.6. Effect of Albumin on EMT and Autophagy Following 72 hours of Treatment 
To examine the effect of albumin on EMT and autophagy, the expression of α-
SMA and LC3-II expression was measured in NRK-52E cells subjected to various 
concentrations of albumin (1 to 30 mg/ml) in 5% FBS containing media for 72 hours. α-
SMA expression increased in a concentration-dependent manner with more than 2-fold 
increase in cells treated with 1 mg/ml of albumin and 6-fold increase in cells treated with 
30 mg/ml of albumin (Figure 3.6). Intriguingly, the levels of LC3-II were unchanged in 
renal cells exposed to low concentrations of albumin (1, 5 and 10 mg/ml). Nonetheless, 
exposure of cells to 15 mg/ml and 30 mg/ml of albumin caused a significant increase in 
LC3-II expression as compared to the control.   
		 49	
 
 
 
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure 3.6. Effect of albumin on EMT and autophagy in NRK-52E cells following 72 
hours of treatment. Upper panel (A) showing a representative western blot, the middle 
(B) and the lower (C) panels showing the densitometry measurements normalized to β-
actin. Values were expressed as Mean ± SEM; n = 3; *P < 0.05 vs. Control.   
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 3.2. EFFECT OF METFORMIN ON SIGNALING PATHWAYS ALTERED BY 
ALBUMIN IN RENAL CELLS 
3.2.1. Effect of Metformin on AMPK Signaling Pathway in Albumin-Induced Renal 
Cell Injury 
  Western blotting followed by densitometry was used to quantify the effect of 
metformin treatment on AMPK phosphorylation in NRK-52E cells exposed to albumin 
(10 mg/ml and 15 mg/ml) in 5% FBS containing media for 48 hours. We noted a 
significant decrease by about 0.5-fold in phospho-AMPK levels with 10 and 15 mg/ml of 
albumin treatment as compared to the control. Metformin treatment was able to prevent 
the reduction in phospho-AMPK expression caused by albumin (Figure 3.7).   
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Figure 3.7. Effect of metformin on phospho-AMPK (Thr172) expression in NRK-52E 
cells following 48 hours of albumin treatment. Upper panel (A) showing a representative 
western blot and the lower panel (B) showing the densitometry measurements normalized 
to β-actin. Values were expressed as Mean ± SEM; n = 3; *P<0.05 vs. untreated control 
(C), # and @ P<0.05 vs. 10 and 15 mg/ml Albumin treated groups respectively. 
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3.2.2. Effect of Metformin on AKT Signaling Pathway in Albumin-Induced Renal 
Cell Injury 
To determine the effect 1 mM of metformin has on phospho-AKT expression in 
our model, western blotting followed by densitometry was used. Subsequent to 48 hours 
of albumin treatment phospho-AKT levels significantly increased by 1.5-fold as 
compared to the control. On the other hand, when cells were co-treated with metformin 
and albumin, the phospho-AKT expression was reduced to 0.5-fold as compared to 
albumin treated groups (Figure 3.8).   
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Figure 3.8. Effect of metformin on phospho-AKT (Ser129) expression in NRK-52E cells 
following 48 hours of albumin treatment. Upper panel (A) showing a representative 
western blot and the lower panel (B) showing the densitometry measurements normalized 
to β-actin. Values were expressed as Mean ± SEM; n = 3; *P<0.05 vs. untreated control 
(C), # and @ P<0.05 Vs. 10 and 15 mg/ml Albumin treated groups respectively. 
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3.2.3. Effect of Metformin on mTOR Signaling Pathway in Albumin-Induced Renal 
Cell Injury 
   Western blotting followed by densitometry was employed to measure changes in 
the expression of downstream targets mTOR pathway - phospho-4EBP-1 and phospho-
p70S6K - following the addition of 1 mM of metformin in the in vitro model. Both 
phospho-4EBP-1 and phospho-p70S6K were found to significantly increase subsequent 
to cellular treatment with 10 mg/ml of albumin. Co-treatment with 10 mg/ml of albumin 
and 1mM of metformin significantly decreased phospho-4EBP-1 (Figure 3.9) and 
phospho-p70S6K (Figure 3.10) to 0.8-fold and 1.2-fold respectively as compared to 
albumin treated groups.  
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Figure 3.9. Effect of metformin on phospho-4EBP1 (Thr37/46) expression in NRK-52E 
cells following 48 hours of albumin treatment. Upper panel (A) showing a representative 
western blot and the lower panel (B) showing the densitometry measurements normalized 
to β-actin. Values were expressed as Mean ± SEM; n = 3; *P<0.05 vs. untreated control 
(C), # and @ P<0.05 vs. 10 and 15 mg/ml Albumin treated groups respectively. 
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Figure 3.10. Effect of metformin on phospho-P70S6K (Thr389) expression in NRK-52E 
cells following 48 hours of albumin treatment. Upper panel (A) showing a representative 
western blot and the lower panel (B) showing the densitometry measurements normalized 
to β-actin. Values were expressed as Mean ± SEM; n = 3; *P<0.05 vs. untreated control 
(C), # and @ P<0.05 vs. 10 and 15 mg/ml Albumin treated groups respectively.  
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3.2.4. Effect of Metformin on Albumin-Induced ER Stress in Renal Cells 
To measure metformin-mediated alterations on albumin-induced ER stress in 
renal cells, western blotting was employed. The expression of ER stress markers GRP78, 
phospho-eIF2⍺ and CHOP was quantified in NRK-52E cells following treatment with 10 
mg/ml and 15 mg/ml of albumin in the presence or absence of metformin for 72 hours.  
Treatments with either 10 mg/ml of albumin or 1 mM of metformin caused a significant 
induction in GRP78 expression. Nonetheless, cells subjected to albumin and metformin 
co-treatment showed profound increase in GRP78 levels as compared to albumin only 
treatment. On the other hand, the induction of other two ER stress markers - phospho-
eIF2⍺ and CHOP - by 10 mg/ml albumin treatment was normalized following co-
treatment with metformin to 0.8-fold and 1.2-fold respectively as compared to control 
(Figure 3.11). Intriguingly, metformin treatment was unable to further increase GRP78 
expression and attenuate the induction of phospho-eIF2⍺ and CHOP in 15 mg/ml 
albumin treated group.  
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Figure 3.11. Effect of metformin on the expression of ER stress markers (GRP78, P-
eIF2α (Ser51) and CHOP) in NRK-52E cells following 72 hours of albumin treatment. 
Upper panel (A) showing a representative western blot and the lower panel (B) showing 
the densitometry measurements normalized to β-actin. Values were expressed as Mean ± 
SEM; n = 3; *P<0.05 vs. untreated control (C), # and @ P<0.05 vs. 10 and 15 mg/ml 
Albumin treated groups respectively. 
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3.2.5. Effect of Metformin on EMT in Albumin-Induced Renal Cell Injury 
Metformin’s effect on ⍺-SMA (a biomarker of EMT) in albumin-induced cell 
injury model was examined following 72 hours of treatment. As shown previously in 
Figure 3.6, albumin treatments (10 mg/ml and 15 mg/ml) induced the expression of ⍺-
SMA in NRK-52E cells. Cellular exposure to metformin for 72 hours in the presence of 
10 mg/ml and 15 mg/ml of albumin caused a significant decrease in the expression of ⍺-
SMA to 0.4-fold and 0.6-fold respectively (Figure 3.12).   
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Figure 3.12. Effect of metformin on the expression of α-SMA (an EMT marker) in NRK-
52E cells following 72 hours of albumin treatment. Upper panel (A) showing a 
representative western blot and the lower panel (B) showing the densitometry 
measurements normalized to β-actin. Values were expressed as Mean ± SEM; n = 3; 
*P<0.05 vs. untreated control (C), # and @ P<0.05 Vs. 10 and 15 mg/ml Albumin treated 
groups respectively. 
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3.2.6. Effect of Metformin on Autophagy in Albumin-Induced Renal Cell Injury 
To determine metformin’s effects on autophagy, the expression of P-ULK and 
LC3-II was measured in NRK-52E cells following metformin and albumin co-treatment 
for 72 hours. Cells that were exposed to 10 mg/ml of albumin showed caused minimal or 
no difference in the expression of both autophagy biomarkers compared to control. Co-
treatment with metformin increased the expression of the autophagy markers in a 
significant manner (P < 0.05) as compared to 10 mg/ml albumin-treated group (Figure 
3.13). Intriguingly, not only the albumin treatment at 15 mg/ml per se increased the 
expression of P-ULK and LC3-II by about 2-folds (P < 0.05) as compared to control, but 
the induction also remained unaltered despite metformin co-treatment.  
		 62	
  
 
 
 
 
 
  
 
 
 
 
 
 
Figure 3.13. Effect of metformin on the expression of autophagy markers P-ULK-1 
(Ser555) and LC3-II in NRK-52E cells following 72 hours of albumin treatment. Upper 
panel (A) showing a representative western blot and the lower panel (B) showing the 
densitometry measurements normalized to β-actin. Values were expressed as Mean ± 
SEM; n = 3; *P<0.05 vs. untreated control (C), # and @ P<0.05 vs. 10 and 15 mg/ml 
Albumin treated groups respectively. 
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3.2.7. Effect of Metformin on Apoptosis in Albumin-Induced Renal Cell Injury 
 The levels of caspase-12 and caspase-3 expression were measured as indices of 
apoptosis using western blotting. Cellular exposure to 10 and 15 mg/ml of albumin for 72 
hours showed a 2-fold increase in both apoptotic markers as compared to the control. 
Metformin treatment caused a significant decrease in caspase-12 expression in 10 and 15 
mg/ml of albumin groups to around 0.5-fold as compared to albumin-treated cells. 
Concurrently, a similar pattern was noted with caspase-3 expression in cells co-treated 
with albumin and metformin in which the caspases-3 levels were normalized to control 
(Figure 3.14).  
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Figure 3.14. Effect of metformin on the expression of apoptotic caspases – 12 and -3 in 
NRK-52E cells following 72 hours of albumin treatment. Upper panel (A) showing a 
representative western blot and the lower panel (B) showing the densitometry 
measurements normalized to β-actin. Values were expressed as Mean ± SEM; n = 3; 
*P<0.05 vs. untreated control (C), # and @ P<0.05 Vs. 10 and 15 mg/ml Albumin treated 
groups respectively. 
Albumin 
10 mg/ml 
+ Met C 15 mg/ml  
15 mg/ml  
+ Met 10 mg/ml  Met 
Caspase-12 
β-Actin 
Caspase-3 
Caspase-12 Caspase-3 
Co
ntr
ol
Me
tfo
rm
in
10
 m
g/m
l A
lb
10
 m
g/m
l A
lb+
 M
et
15
 m
g/m
l A
lb
15
 m
g/m
l A
lb+
 M
et
Co
ntr
ol
Me
tfo
rm
in
10
 m
g/m
l A
lb
10
 m
g/m
l A
lb+
 M
et
15
 m
g/m
l A
lb
15
 m
g/m
l A
lb+
 M
et
0.0
0.5
1.0
1.5
2.0
2.5
   
   
N
or
m
al
iz
ed
  p
ro
te
in
 e
xp
re
ss
io
n 
   
 
#
*
@
*
#
*
@
*
A 
B 
		 65	
3.3. EFFECTS OF AMPK INHIBITION (USING COMPOUND C) ON EMT, 
AUTOPHAGY, AND APOPTOSIS IN ALBUMIN-INDUCED RENAL CELL 
INJURY 
3.3.1. Concentration-Response Study of Compound C in NRK-52E Cells 
  To identify an optimal concentration of compound C (CC) that would cause a 
significant AMPK inhibition without substantial cytotoxicity, a concentration-response 
study was conducted. The screened concentrations of compound C ranged from 0.05 to 
50 µM. Compound C was found to be cytotoxic even at concentration as low as 1 µM. 
Hence, the optimal concentration for compound C was concluded to exist between 0.05 
and 0.5 µM (Figure 3.15).   
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Figure 3.15. Effect of different concentrations of compound C (CC) on β-Actin 
expression in NRK-52E cells following 48 hours of treatment.  
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3.3.2. Effect of Compound C on AMPK Signaling Pathway in Albumin-Induced 
Renal Cell Injury 
Further to determining the tolerable range of concentrations of compound C in our 
model, we determined the ability of these concentrations to cause a significant AMPK 
inhibition. We found that treatments with compound C at lower concentrations - 0.05 µM 
and 0.1 µM - failed to inhibit metformin-induced phosphorylation of AMPK. 
Nevertheless, co-treatment with 0.5 µM of compound C significantly reduced metformin-
induced AMPK phosphorylation (p<0.05).   
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Figure 3.16. Effect of different concentrations of compound C (0.05 to 0.5 µM) on 
AMPK (Thr172) signaling in NRK-52E cells in the presence and absence of metformin 
following 48 hours of treatment. Upper panel (A) showing a representative western blot 
and the lower panel (B) showing the densitometry measurements normalized to β-actin. 
Values were expressed as Mean ± SEM; n = 3; * p<0.05 vs. untreated control and # 
p<0.05 vs. Metformin treated group.  
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3.4. EFFECT OF AMPK INHIBITION (USING COMPOUND C) ON ALBUMIN-
INDUCED RENAL CELL INJURY 
To determine whether the observed effects of metformin are mediated by AMPK, 
we conducted co-incubation studies with compound C (an inhibitor of AMPK) in our 
model. Western blotting was performed to quantify the effects of compound C on the 
markers of ER stress, EMT, autophagy and apoptosis.  
 
3.4.1. Effects of Compound C on AMPK Phosphorylation in Albumin-induced 
Renal Cell Injury 
Western blotting followed by densitometry was performed to quantify the effects 
0.5 µM of compound C has on the AMPK phosphorylation in the presence and absence 
of albumin and/or metformin. Consistent with our previous findings, treatment with 1 
mM metformin for 48 h caused a 2-fold induction in phospho-AMPK levels in our 
model.  Co-incubation of cells with compound C significantly attenuated metformin-
mediated AMPK phosphorylation in our model (Figure 3.17).  
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Figure 3.17. Effect of compound C on phospho-AMPK (Thr172) expression in NRK-52E 
cells following 48 hours of treatment. Upper panel (A) showing a representative western 
blot and the lower panel (B) showing the densitometry measurements normalized to β-
actin. Values were expressed as Mean ± SEM; n = 3; * P<0.05 Vs. untreated control (C), 
# P<0.05 Vs. Albumin treated groups, and $ P<0.05 Vs. Albumin and Metformin co-
treated group. 
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3.4.2. Effects of Compound C on ER Stress in Albumin-induced Renal Cell Injury 
  To determine whether the observed beneficial effects of metformin on ER stress 
(shown in Figure 3.11) were mediated through AMPK activation, the levels of ER stress 
markers GRP78 and phosphorylated eIF2α were assessed following the addition of 0.5 
µM of compound C in our model. Our studies demonstrate that compound C per se 
significantly decreases the levels of GRP78. On the other hand, cellular co-treatment of 
compound C with metformin in the presence or absence of albumin showed a significant 
decrease in GRP78 expression as compared to albumin and metformin treated group.  
  Intriguingly, the phosphorylation of eIF2α in the presence of compound C 
showed an opposite trend to that of GRP78. For instance, compound C per se 
significantly increased the phospho-eIF2α levels as compared to the control. However, 
addition of compound C to cells co-treated with albumin and metformin had no 
significant effect on eIF2α phosphorylation as compared to albumin and metformin 
treated group (Figure 3.18).   
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Figure 3.18. Effect of compound C on ER stress markers (GRP78 and P-eIF-2α (Ser51)) 
in NRK-52E cells following 72 hours of treatment. Upper panel (A) showing a 
representative western blot and the lower panel (B) showing the densitometry 
measurements normalized to β-actin. Values were expressed as Mean ± SEM; n = 3; * 
P<0.05 vs. untreated control (C), # P<0.05 vs. Albumin treated group, and $ P<0.05 vs. 
Albumin and Metformin co-treated group. 
A 
P-eIF2α 
GRP78 
β -Actin 
Alb 
+Met C CC 
CC 
+ Met Alb  Met 
CC 
+Alb 
CC + Alb  
+ Met
GRP78 P-eIF2α (Ser51) 
B 
C
Me
t
Al
b
Al
b+
Me
t
CC
CC
 + 
Me
t
CC
+ A
lb
CC
+ M
et+
 A
lb C Me
t
Al
b
Al
b+
Me
t
CC
CC
 + 
Me
t
CC
+ A
lb
CC
+ M
et+
 A
lb
0
1
2
3
4
   
 N
or
m
al
iz
ed
  p
ro
te
in
 e
xp
re
ss
io
n 
   
  
*
*
#
*
#
*
*
* *
$
#
		 73	
3.4.3. Effects of Compound C on EMT in Albumin-induced Renal Cell Injury 
To identify the mechanism by which metformin exerts its protective effects against 
EMT, compound C was used to inhibit AMPK mediated effects of metformin. α-SMA 
expression was used as a biomarker for EMT. Consistent with our previous findings (as 
shown in Figure 3.12), exposure to albumin treatment caused a significant induction of 
α-SMA expression, which was attenuated in metformin co-treated group. However, no 
difference was detected between compound C, metformin and albumin treated group as 
compared to albumin and metformin co-treated arm (Figure 3.19).  
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Figure 3.19. Effect of compound C on α-SMA (an EMT marker) expression in NRK-52E 
cells following 72 hours of treatment. Upper panel (A) showing a representative western 
blot and the lower panel (B) showing the densitometry measurements normalized to β-
actin. Values were expressed as Mean ± SEM; n = 3; *P<0.05 Vs. untreated control (C) 
and  # P<0.05 Vs. Albumin treated group. 
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3.4.4. Effects of Compound C on Autophagy in Albumin-induced Renal Cell Injury 
To assess the effects of AMPK inhibition on cellular autophagy, the expression of 
LC3-II was measured in the presence of compound C in our model. Our data revealed a 
significant attenuation of LC3-II expression in cells treated with compound C, metformin 
and albumin as compared to cells that were only co-treated with albumin and metformin 
(Figure 3.20).  
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 Figure 3.20. Effect of compound C on autophagy marker LC3-II in NRK-52E cells 
following 72 hours of treatment. Upper panel (A) showing a representative western blot 
and the lower panel (B) showing the densitometry measurements normalized to β-actin. 
Values were expressed as Mean ± SEM; n = 3; *P<0.05 Vs. untreated control (C), # 
P<0.05 Vs. Albumin treated group, and $ P<0.05 Vs. Albumin and Metformin co-treated 
group. 
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3.4.5. Effects of Compound C on Apoptosis in Albumin-induced Renal Cell Injury 
  To study whether the anti-apoptotic effects of metformin were AMPK mediated 
or not, caspase-12 and BAX expressions were measured in presence of compound C in 
our in vitro model. The expression of both caspase-12 and BAX was found to 
significantly increase in the presence of compound C alone and the degree of induction 
was similar to that of the albumin-treated group. Interestingly, metformin retained its 
anti-apoptotic effects - evidenced by the normalization of caspase-12 and BAX levels - in 
albumin treated NRK-52E cells despite AMPK inhibition through compound C (Figure 
3.21).  
 
  A summary of the effects of albumin, metformin and compound C treatment in 
NRK-52E cells on AMPK, AKT and mTOR signaling pathways following 48 hours of 
treatment and on ER stress, EMT, autophagy and apoptosis makers were represented in 
the Table 3.1.   
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Figure 3.21. Effect of compound C on pro-apoptotic proteins – Caspase-12 and BAX - in 
NRK-52E cells following 72 hours of treatment. Upper panel (A) showing a 
representative western blot and the lower panel (B) showing the densitometry 
measurements normalized to β-actin. Values were expressed as Mean ± SEM; n = 3; 
*P<0.05 vs. untreated control (C) and # P<0.05 vs. Albumin treated group. 
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Table 3.1. 
Summary of the effects of albumin, metformin and compound C in the established in 
vitro model of proteinuric kidney disease. The upward (↑) and downward (↓) arrows 
represent upregulation and downregulation of the protein of interest respectively. Double 
upward arrows indicate profound induction of protein expression as compared to 
albumin-treated group. 
 
 
Protein of interest Albumin Metformin Compound C 
AMPK Signaling 
P-AMPK ↓  ↑  ↓  
AKT Signaling 
P-AKT ↑  ↓  - 
mTOR Signaling 
P-4EBP-1 ↑  ↓  - 
P-P70S6K ↑  ↓  - 
ER Stress 
GRP78 ↑  ↑↑  ↓  
P-eIF2α ↑  ↓  No change 
CHOP ↑  ↓  - 
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Protein of interest Albumin Metformin Compound C 
EMT 
α-SMA ↑  ↓  No change 
Autophagy 
P-ULK-1 ↑  ↑↑  ↓  
LC3-II ↑  ↑↑  ↓  
Apoptosis 
Caspase-12 ↑  ↓  No change 
Caspase-3 ↑  ↓  - 
BAX ↑  ↓  No change 
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Chapter 4: Discussion 
In the current study, immortalized rat proximal tubular epithelial cells (NRK-52E 
cells) were exposed to different concentrations of albumin that mimics conditions 
observed in CKD. Following standardization of a cellular model of CKD, the effects of 
metformin, a widely used anti-diabetic drug, was tested for its ability to modulate AMPK, 
AKT, and mTOR pathways, ER stress, EMT, autophagy and apoptosis. Furthermore, 
compound C, an AMPK inhibitor, was used to differentiate between the AMPK-
dependent and AMPK-independent effects of metformin.   
4.1. AMPK PHOSPHORYLATION 
Our study for the first time indicates that exposure to albumin (at concentrations 
10 and 15 mg/ml) causes a significant decrease in the phosphorylation of AMPK in renal 
cells, and metformin treatment reverses albumin’s effect on AMPK phosphorylation. A 
previous study in human proximal tubular cell line (HK-2 cells) by Lee et al. (2012) used 
5 mg/ml concentration of albumin but failed to showed changes in phospho-AMPK levels 
as compared to the control (92). This discrepancy in comparison to our findings could be 
attributed to the suboptimal concentration of albumin (i.e., 5 mg/ml) used in their study. 
Although we noted an increase in the expression of phospho-AMPK in metformin treated 
cells as compared to the control, the increase was not statistically significant. Using a 
similar cell line, Li et al. (2016) showed a similar pattern of a non-significant increase in 
AMPK phosphorylation in metformin treated cells as compared to the control (93). Thus, 
our findings with metformin in albumin-treated cells are in close alignment with the 
above study (92) and other models of kidney injury such as hypoxia-induced renal injury 
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(94), gentamicin-induced acute renal failure (95) and contrast-induced acute kidney 
injury (96).  
To determine an optimal concentration of compound C in our cellular model, we 
tested different concentrations of compound C for their activity against AMPK 
phosphorylation with little or no cytotoxicity. This is because compound C was shown to 
be cytotoxic in various in vivo and in vitro models of astroglioma (97, 98). For instance, 
compound C (at 10 µM concentration) was shown to effectively diminish astrocytic 
tumors proliferation and growth (97). Subsequently, as study by Liu et al. (2014) revealed 
that concentrations as low as 1 µM for 72 hours causes significant cytotoxicity in three 
different glioma cell lines (99). The aforementioned cytotoxic effects of compound C 
could be explained by its ability to bind to a range of kinases other than AMPK (100, 
101). For instance, studies conducted in zebra fish embryos revealed compound C’s 
potent inhibitory action on bone morphogenetic protein (BMP) signaling (102); in 
particular, Yu et al. (2008) showed a significant decrease in BMP type I receptors and 
BMP-mediated phosphorylation of SMAD1/5/8 following treatment with compound C at 
concentrations ranging from 1 to 4 µM (102). Furthermore, a full-scale SAR study 
performed in vertebrates to screen for the effects of compound C and its analogs on cell 
signaling showed that compound C is a potent inhibitor of vascular endothelial growth 
factor (VEGF) type-II receptor at concentrations ranging from 5 to 10 µM (103).  
It is remarkable to note that studies using non-cancerous cell lines to understand 
the effects of compound C on the phosphorylation of AMPK are scarce. Studies in cancer 
cell lines such as glioma (99) and human fibrosarcoma (104) indicate that concentrations 
ranging from 5 µM to 10 µM of compound C are required to cause a significant inhibition 
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of AMPK phosphorylation. In our studies, we found that the use of compound C at 0.5 
µM concentration caused significant inhibition of metformin-induced AMPK 
phosphorylation without substantial cytotoxicity.  
4.2. MTOR PATHWAY 
Our study showed that cellular exposure to albumin leads to a significant increase 
in mTOR activation portrayed by an increase in 4EBP-1 and P70S6K phosphorylation. 
mTOR pathway modulation was extensively studied in different renal disease states (105, 
106). Intriguingly, the effects of mTOR activation vary significantly depending on the 
type of renal injury. For instance, inhibition of mTOR activation with rapamycin (an 
mTOR inhibitor) in renal ischemia-reperfusion injury, delayed the rate of renal recovery 
and repair as compared to cells in which mTOR was not inhibited (106). These effects 
could be explained by the proliferative and regenerative properties mediated through 
mTOR, which are essential in the restoration of glomerular filtration following AKI 
(106). In contrast, the proliferative and regenerative effects of mTOR were found to 
exacerbate CKD and diabetic nephropathy through stimulation of the extracellular matrix 
protein synthesis, leading to basement membrane thickening and mesangial matrix 
enlargement, and ultimately into glomerular hypertrophy (105). Additionally, data from 
animal studies showed that rapamycin-mediated inhibition of mTOR significantly 
ameliorated interstitial inflammation, fibrosis, and loss of renal function associated with 
CKD (105, 106). In our study, albumin was used to evoke cellular responses that mimic 
those observed in cases of CKD. Therefore, an increase in mTOR activity caused by 
albumin in our model was anticipated. In corroboration to our findings, a study by Lee et 
al. (2010) in which renal proximal tubular cells were exposed to 5 mg/ml of albumin for 
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5 days also showed a significant increase in mTOR activity as compared to the control 
(107). 
Our findings also demonstrated that 1 mM of metformin was able to significantly 
reduce mTOR activity induced by albumin. A similar inverse association between AMPK 
and mTOR pathway is also shown in many cell types such as hepatocytes (108), airway 
smooth muscle cells (98) and cellular models of cancer (109, 110). For example, studies 
by Dowling et al. (2007) in MCF-7 breast cancer cells demonstrated that metformin 
treatment blocks the phosphorylation of P70S6 kinase and eIF4E-1, the makers of mTOR 
activation in cells. The study also indicated that the effect metformin had on mTOR 
pathway was AMPK dependent, as these effects were diminished in presence of 
compound C (111). Comparably, data from renal injury models further indicate the 
inhibitory effects of metformin on mTOR pathway. Consensus with our findings, Liu et 
al. (2013) and Declèves et al. (2014) demonstrated that metformin treatment stimulates 
AMPK phosphorylation and blocks mTOR pathway in vitro and in vivo in renal cells (63, 
112).  
4.3. P-AKT PATHWAY 
 We found that exposure to albumin per se for 48 hours induces significant AKT 
phosphorylation in our model. Similar to our findings, Jones et al. (2003) reported a 
significant increase in AKT phosphorylation in B-chronic lymphocytic leukemia (CLL) 
cells following treatment with 25 mg/ml of human albumin for 24 hours (113). 
Additionally, the AKT activation was reported to play a key role in the progression of 
renal carcinoma (114). The direct evidence for the role of AKT in CKD was 
demonstrated in a study by Canaud et al. (2013), which measured AKT activity in 
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podocytes extracted from patients with different forms of CKD. In line with our findings, 
the study showed that AKT phosphorylation was significantly increased in all forms of 
CKD (115). 
 Further, we studied the effects of metformin treatment for 48 hours on AKT 
pathway in our cellular model. Similar to our findings with the mTOR pathway, 
metformin was able to restore phospho-AKT activity in renal cells exposed to albumin. 
Congruent with our findings, metformin was shown to inhibit AKT activation in breast 
cancer cells (111). In addition, metformin’s effects on AKT were reported to be AMPK-
dependent as silencing of AMPK activity using siRNA blocked metformin’s effect on 
AKT pathway in these cells (111). 
4.4. ER STRESS 
As previously described, the accumulation of misfolded proteins within the 
endoplasmic reticulum is the principal stimulus for ER stress. To protect cells from 
transient ER stress, unfolded protein response is triggered, through which, the cellular 
structure and function is preserved. One of the mechanisms by which transient UPR 
maintains ER homeostasis is by increasing the levels of GRP78 (the ER chaperone) and 
via phosphorylation of eIF2α, which inhibits the translation of new proteins (92). In 
contrast, prolonged ER stress induces CHOP, which promotes ER stress mediated 
apoptosis (116). To characterize the nature of albumin-induced ER stress, we measured 
the effects of albumin on GRP78, phospho-eIF2α and CHOP. We found that albumin 
significantly increased the expression of CHOP in addition to induction of GRP78 and 
phosphorylation of eIF2α. In consensus with our findings, Lee et al. (2012) reported a 
significant increase in the levels of GRP78 and P-eIF2α in human proximal tubular cells 
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(HK-2) following 3 days’ exposure to 5 mg/ml of albumin (92). Similarly, the expression 
of CHOP increased significantly following albumin treatment in proximal tubular cells 
(117). In support to in vitro studies, findings by Ohse et al. (2006) in proteinuric rat 
kidneys reveal a prominent induction of GRP78 in proximal and distal tubules, which is 
otherwise restricted to distal tubules in normal rat kidneys (118).  
Further, we studied metformin-mediated alterations on albumin-induced ER stress 
in our model. Intriguingly, a paradoxical increase in GRP78 levels was noted following 
metformin treatment as compared to albumin only treated cells. These findings could be 
explained by the unique functions of transient UPR activation and its anti-apoptotic 
effects mediated through the ER chaperone GRP78 (119). As a multi-functional protein 
GRP78 assists in several process such as protein folding and assembly, translocation of 
newly synthesized proteins across the ER and initiation of ER-associated degradation 
(ERAD) to degrade misfolded proteins. The sum of the described functionalities 
mediated through GRP78 decreases ER stress and thereby, promotes cellular survival 
(119). The observed increase in GRP78 expression in renal cells subjected to metformin 
treatment might be an early compensatory mechanism through which ER machinery 
attempts to minimize ER stress. Paradoxical to our findings, a similar study by Lee et al. 
(2012) reported a 2-fold reduction in the levels of GRP78 following 48 h metformin 
treatment in HK-2 cells that were pretreated with albumin for 72 h (92). However, the 
discrepancy could be attributed to the differences in treatment protocol, i.e. albumin pre-
treatment and limited duration of metformin treatment. Our studies also demonstrated 
that metformin causes a significant decrease in the phosphorylation of eIF2α, indicative 
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of attenuation of new protein translation, which is consistent with the findings from Lee 
et al. (2012) (92).  
In our model, CHOP expression significantly decreased following metformin 
treatment signifying a potential inhibition to its pro-apoptotic properties. Intriguingly, 
metformin’s effect on CHOP seems to be controversial in the literature and is highly 
dependent on the cellular model and the concentration used. For instance, a study by 
Leclerc et al. (2013), which investigated the effects of metformin (5 mM) in acute 
lymphoblastic leukemia (ALL), reported a significant increase in IRE1α and CHOP, and 
a resultant increase in UPR-mediated cell death (120). In contrast, Kim et al. (2010) 
demonstrated that 0.5 mM of metformin was able to lower CHOP levels in palmitate-
induced ER stress in HepG2 cells (121). The differential alterations in the expression of 
CHOP by metformin can be attributed to the differences in the concentrations used (i.e. 
0.5 mM vs. 5mM). Our findings in conjunction with reported studies suggest a 
concentration-dependent modulation of ER stress by metformin, i.e., anti-ER stress 
properties at lower concentrations and pro-ER stress and apoptosis at higher 
concentrations.  
To identify whether metformin’s effects on ER stress were mediated through 
AMPK pathway, we used compound C to inhibit metformin-mediated AMPK 
phosphorylation in cells exposed to albumin. Intriguingly, we found that metformin’s 
induction of GRP78 was AMPK-dependent whereas eIF2α inhibition was AMPK-
independent. It is important to note GRP78 is involved in all UPR pathways including 
IRE1α, ATF6α and PERK, while the eIF2α is a downstream target for PERK pathway. 
Therefore, our finding denotes that PERK inhibition is AMPK-independent while the 
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metformin’s effects on IRE1α and/or ATF6α may or may not be AMPK-dependent. 
Congruently, Gomez et al. (2008) demonstrated that the use of AICAR (a specific AMPK 
activator) in a model of glucose-stimulated ER stress in pancreatic cells had no effect on 
the phosphorylation of eIF2α. Taken together, it is clear that PERK modulation is 
independent of AMPK status in cells (122). Moreover, studies conducted in mouse 
embryonic fibroblast and Phoenix cells to investigate the effects of AMPK on IRE1α 
pathway revealed that phenformin (an analog of metformin) activates IRE1α signaling 
pathway in an AMPK-dependent manner (123). However, metformin-mediated 
modulation of ATF6α and its dependency on AMPK status are yet to be evaluated.  
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4.5. EMT  
To determine the effects of albumin on EMT, we examined for alterations in the 
expression of α-SMA following cellular exposure to albumin. As expected, cellular 
treatment with albumin for 72 hours increased α-SMA significantly, indicating the 
involvement of EMT in albumin-induced renal injury. Consistently, studies by Hu et al. 
(2015) and Ibrini et al. (2012) in rat renal tubular cells revealed a clear induction in EMT 
- marked by a decrease in the levels of epithelial marker E-cadherin and an increase in the 
expression of mesenchymal markers - fibroblast-specific protein 1, α-smooth muscle 
actin and collagen I - following exposure to albumin (124, 125). 
To determine the anti-fibrotic effects of metformin, i.e. to inhibit epithelial-
mesenchymal transformation, we examined the metformin-induced changes to α-SMA 
levels in our cell model. Our studies demonstrate that metformin prevents albumin-
induced EMT - evident from a significant decrease in α-SMA expression with metformin 
treatment. Consistent with our findings, Lee et al. (2013) showed a significant 
suppression in albumin-induced EMT in human proximal tubular cell line following 
metformin treatment (78). Furthermore, the study postulated that metformin mediated 
EMT inhibition maybe due to its inhibitory action on ROS (78). 
Intriguingly, we found that metformin’s effects on albumin-induced EMT are not 
AMPK-dependent. This was evident from metformin’s persistent inhibitory effect on α-
SMA expression despite AMPK inhibition using compound C. In consensus with our 
findings, Liu et al. (2016) also reported that the addition of compound C to metformin in 
KLE cells did not change metformin’s ability to prevent EMT (126). Thus, our study 
indicates that metformin’s inhibitory effects on EMT are AMPK-independent.  
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4.6. AUTOPHAGY 
We found that NRK-52E cells subjected to lower concentrations of albumin 
showed minimal or no changes in the expression of autophagy marker LC3II as 
compared to the control. Nonetheless, exposure to higher concentrations of albumin 
caused a significant increase in LC3-II levels in NRK-52E cells. Our findings indicate a 
concentration-dependent activation of autophagy by albumin in renal cells. This is in 
close correlation with the findings from a study by Liu et al. (2014), which reported only 
a slight increase in the number of LC3-II positive immunofluorescence staining puncta in 
HK-2 cells when treated with lower concentration of urinary proteins (0.5 to 1 mg/ml) as 
compared to the control (127). Increasing the concentration of urinary proteins to 8 
mg/ml was shown to cause a significant elevation in LC3-II expression detected by 
western blotting and immunofluorescence staining (127). Remarkably, immunostaining 
of kidneys obtained from rats injected with cationic bovine serum albumin (C-BSA) 
revealed a significant elevation in the amount of LC3-II puncta as compared to healthy 
rat kidneys (127). 
Following standardization of the albumin-induced renal injury model, we studied 
the effects of metformin on autophagy. This was done via determining the 
phosphorylation of ULK-1 and the expression of LC3-II in cells subjected to metformin 
co-treatment as compared to the albumin-treated group. Induction of P-ULK-1 and LC3-
II expression in renal cells revealed that metformin significantly induced autophagy. In 
conjunction with our findings, Li et al. (2016) also reported a prominent induction of 
autophagy following metformin treatment in cisplatin-induced renal injury model (93).  
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Furthermore, when cells were subjected to compound C in the presence of 
metformin in our albumin-induced renal injury model, metformin’s activation of 
autophagy was abolished indicating that metformin’s effects on autophagy are AMPK-
dependent. In agreement with our findings, Li et al. (2016) and Wang et al. (2013) 
revealed through chemical inhibition and small hairpin shRNA silencing of AMPK that 
metformin induces autophagy through AMPK activation in cisplatin and 
ischemia/reperfusion-induced renal tubular cell injury models respectively (93, 128).   
 4.7. APOPTOSIS 
The effects of 10 mg/ml and 15 mg/ml of albumin on apoptosis in NRK-52E cells 
were quantified through determining the differences in caspase-12 and caspase-3 
expression in cells subjected to albumin for 72 hours. We showed a statistically 
significant 2-fold induction in the expression of both caspase-12 and caspase-3 following 
albumin treatment as compared to the control. Our findings suggest that albumin induces 
apoptosis in renal tubular cells. In further support to our findings, a study by Ohse et al. 
(2006) in immortalized rat proximal tubule cells (IRPTC) also revealed apoptotic cellular 
alterations such as nuclear shrinkage and condensation following albumin treatment at 
concentrations ranging from 10 mg/ml to 40 mg/ml. In addition, the extent of apoptosis 
was then confirmed using Annexin V assay (118). Similarly, Wu et al. (2010) and 
Fontana et al. (2015) also reported albumin-induced apoptosis in proximal tubule cells 
(117, 129).  
To study metformin’s protective effects against albumin-induced apoptosis, 
changes in the expression of apoptotic markers caspase-12 and caspase-3 were measured 
following metformin treatment in our model. Our findings indicate that metformin 
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treatment attenuates albumin-mediated induction of caspases-12 and caspase-3 and 
protects renal cells from apoptosis. Similarly, multiple studies revealed metformin’s 
protective effects on renal cell apoptosis. For instance, in a model similar to this study, 
Lee et al. (2012) showed that albumin-induced apoptosis was prevented by metformin, 
which was marked by a reduction in the caspase-3 expression (92). It is interesting to 
note that metformin’s renoprotective effects were not limited to albumin-mediated 
apoptosis and extends to other models of renal injury. For example, metformin’s ability 
to inhibit apoptosis in renal cells was also demonstrated in in vivo models of gentamycin-
induced (95) and renal ischemia/reperfusion-induced (130) renal cell apoptosis.  
Using compound C mediated chemical inhibition of AMPK, we determined that 
metformin’s anti-apoptotic effects are not AMPK mediated. This was evident through no 
alterations to the metformin-mediated reduction in caspase-12 and BAX expression 
following compound C treatment in our model. Intriguingly, the majority of studies that 
investigated the  link between AMPK activation and the anti-apoptotic effects of 
metformin are conducted in cancerous cell lines. In consensus with our findings, 
Janjetovic et al. (2010) demonstrated that metformin prevents cisplatin-induced apoptosis 
in U251 glioma cells through blockade of oxidative stress and caspase activation (131). 
Furthermore, metformin’s cytoprotective action was shown to be AMPK-independent as 
the use of other AMPK activators such as AICAR did not prevent cisplatin-mediated 
apoptosis (131).  
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Chapter 5: Conclusion 
The current study indicates that in vitro exposure to albumin inhibits AMPK but 
activates AKT and mTOR pathways, and induces ER stress, EMT, autophagy and 
cellular apoptosis. Furthermore, metformin’s reno-protective effects against proteinuric 
cytotoxicity are exerted via the inhibition of AKT and mTOR signaling pathways and the 
attenuation of EMT and apoptosis. Additionally, treatment with metformin significantly 
augments cytoprotective mechanisms such as autophagy and ER defense response in 
renal tubular cells. Studies with Compound C reveal that metformin’s effects on 
autophagy and ER chaperone expression are AMPK-mediated whereas its effect on EMT 
and apoptosis are independent of AMPK activation (Figure 5.1).   
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Figure 5.1. Signaling pathways through which metformin exerts its AMPK-dependent 
and AMPK-independent effects on albumin-induced renal cell injury. 
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5.1. CLINICAL IMPLICATIONS  
Our study unveiled the potential therapeutic effects of metformin in preventing the 
development and progression of CKD (Figure 5.2). In alignment with the revised 
guidelines from the US FDA, metformin could be used in patients with stages 1 and 2 of 
CKD without any dose-reduction and in patients with stage 3A of CKD with 50% dose-
reduction (7). In support to our findings, multiple studies in vivo revealed metformin’s 
ability to ameliorate tubular injury associated with hyperglycemia (93, 94, 132). 
Nonetheless, clinical trials in patients with established renal injury are yet to be 
performed to ascertain the therapeutic potential of metformin in the management of 
CKD.  
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Figure 5.2. Potential therapeutic uses of metformin therapy in patients with CKD.   
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  5.2. FUTURE DIRECTIONS 
• One major limitation of our study is the use of a chemical inhibitor for 
AMPK, i.e., compound C, which is known for its non-specific effects and 
potential cytotoxicity. Thus, to validate the findings from compound C 
studies, an siRNA-mediated AMPK gene silencing in NRK-52E cells could be 
considered. 
• To validate our findings in vivo, an animal model with renal-specific deletion 
of both AMPKα1 and α2 catalytic subunits (133) could be used to dissect 
AMPK-dependent and independent effects of metformin.  
• Studies to delineate the AMPK-independent pathways such as blockade of 
HIF-1 activation (94), TGF-β expression (134) and ROS production (95) 
through which metformin could inhibit EMT and apoptosis would unveil 
novel drug targets for the treatment of CKD.  
• One of the main phenomenon that was discussed in our study is autophagy 
nonetheless, its effects on metformin-mediated cell survival were not 
explored. Therefore, studying the consequences of attenuation of autophagy 
on metformin’s protective effects would be an intriguing area to investigate.  
• To study the effects of metformin on UPR, we investigated its effects on 
proteins regulated by all 3 pathways (i.e. GRP78 and CHOP) in addition to its 
effects on PERK pathway (P-eIF2α). Nonetheless, metformin’s effects on 
IRE1 and ATF6 pathways are yet to be explored. Hence, investigating the 
effects of metformin on XBP-1 and P50, the downstream targets of IRE1 and 
ATF6, would be an interesting area of research. 
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